Pancreatic Cancer Research

ResearcherErasmus MCNo recent work listed

Leo J. Hofland

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4897-2197; OpenAlex author ID A5006066076. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper

Papers 12

  1. Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3. Co-author PMID 37424830↗
  2. The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation. Last author DOI 10.3390/biomedicines10030517↗
  3. Immunomodulatory antitumor effect of interferon‑beta combined with gemcitabine in pancreatic cancer. Last author DOI 10.3892/ijo.2022.5387↗
  4. Type I interferons in pancreatic cancer and development of new therapeutic approaches. Last author DOI 10.1016/j.critrevonc.2020.103204↗
  5. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer. Last author DOI 10.1186/s12885-020-07420-0↗
  6. Potentials of interferon therapy in the treatment of pancreatic cancer. First author DOI 10.1089/jir.2014.0157↗
  7. IFN-β is a potent inhibitor of insulin and insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells. Last author PMID 26269762↗
  8. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Co-author DOI 10.1038/cgt.2013.78↗
  9. Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells. Last author DOI 10.1111/jcmm.12200↗
  10. Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy? Co-author DOI 10.2174/1568009611313040008↗
  11. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Co-author DOI 10.1016/j.biotechadv.2011.08.001↗
  12. Type I interferons as radiosensitisers for pancreatic cancer. Co-author DOI 10.1016/j.ejca.2011.03.009↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Casper H.J. van Eijck · 10 shared papers, 2011–2023 · strength 1.12
  2. Amber Blaauboer · 4 shared papers, 2020–2022 · strength 0.64
  3. Dana A. M. Mustafa · 3 shared papers, 2022–2023 · strength 0.52
  4. Stephanie Booy · 4 shared papers, 2014–2020 · strength 0.32
  5. Casper W.F. van Eijck · 1 shared paper, 2023 · strength 0.19
  6. Hassana el Haddaoui · 1 shared paper, 2023 · strength 0.19
  7. Michail Doukas · 1 shared paper, 2023 · strength 0.19
  8. Kostandinos Sideras · 1 shared paper, 2021 · strength 0.19
  9. Alessandra Dicitore · 2 shared papers, 2012–2013 · strength 0.06
  10. Michele Caraglia · 2 shared papers, 2012–2013 · strength 0.06
  11. Giovanni Vitale · 2 shared papers, 2012–2013 · strength 0.06
  12. Pascal Buijs · 1 shared paper, 2014 · strength 0.06
  13. Bernadette G. van den Hoogen · 1 shared paper, 2014 · strength 0.06
  14. Marjolein J. M. Morak · 1 shared paper, 2011 · strength 0.03
  15. Alfredo Budillon · 1 shared paper, 2012 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.